Recurrent aciclovir-resistant herpes simplex in a child with Wiskott- Aldrich syndrome

British Journal of Dermatology

Volumn 139, Issue 2, 1998, Pages 311-314

  Saijo, M ^a,b   Suzutani, T ^a   Murono, K ^a   Hirano, Y ^a   Itoh, K ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VIDARABINE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; SCHOOL CHILD; VIRUS RESISTANCE; WISKOTT ALDRICH SYNDROME;

ACYCLOVIR; ANTIVIRAL AGENTS; CHILD; DRUG RESISTANCE, MICROBIAL; HERPES SIMPLEX; HUMANS; MALE; OPPORTUNISTIC INFECTIONS; RECURRENCE; WISKOTT-ALDRICH SYNDROME;

EID: 0031867822     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02374.x     Document Type: Article

References (13)

1. Modiano P, Salloum E, Gillet-Terver MN et al. Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome. Br J Dermatol 1995; 133: 475-8.
2. Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161: 1078-84.
3. Safrin S, Crumpacker C, Chatis P et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551-5.
4. Jamieson AT, Gentry GA, Subak-Sharp JH. Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. J Gen Virol 1974; 24: 465-80.
5. Suzutani T, Machida H, Sakuma T. Efficacies of antiherpesvirus nucleotides against two strains of herpes simplex virus type 1 in Vero cells and human embryo lung fibroblast cells. Antimicrobiol Agents Chemother 1988; 32: 1046-52.
6. Elion GB, Furman PA, Fyfe JA et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74: 5716-20.
7. Plunkett W, Cohen SS. Two approaches that increase the activity of adenosine nucleosides in animal cells. Cancer Res 1975; 35: 1547-54.
8. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrobiol Agents Chemother 1991; 35: 2322-8.
9. Sibrack CD, Gutman LT, Wilfert CM et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 1982; 146: 673-82.
10. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multi-institutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125: 876-85.
11. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 1990; 263: 1662-4.
12. Washio M, Hamada T, Goda H et al. Aciclovir-resistant herpes zoster encephalitis successfully treated with vidarabine: a case report. Fukuoka Acta Med 1993; 84: 436-9.
13. Nagafuchi S, Moriyama K, Takamatsu Y et al. Treatment of disseminated herpes zoster in six severely immunocompromised patients: acyclovir and vidarabine. Jpn J Med 1989; 28: 100-4.